Loading organizations...
§ Private Profile · Boston, MA, USA
Biotech develops the iGPS® in vivo gene delivery platform for genetic medicines, focused on immunology and oncology.
Kelonia Therapeutics, based in Boston, Massachusetts, develops a next-generation in vivo gene delivery platform, iGPS®, designed for precise and efficient delivery of genetic medicines. This platform employs lentiviral vector-like particles to address a broad spectrum of diseases, with a particular focus on immunology and oncology. The company secured $50 million in Series A financing, led by Alta Partners, with participation from Horizons Ventures and Venrock. Kelonia has also established a research collaboration and licensing deal with Xyphos Biosciences, an Astellas subsidiary, for immuno-oncology programs, potentially valued at up to $800 million. The organization was founded in 2022 by Kevin Friedman, Michael Birnbaum, and Michael Fischbach. Its business model centers on venture capital-funded biotech with revenue from research collaborations, licensing agreements, and milestones.
Kelonia Therapeutics has raised $50.0M across 1 funding round.
Kelonia Therapeutics has raised $50.0M in total across 1 funding round.
Kelonia Therapeutics has raised $50.0M in total across 1 funding round.
Kelonia Therapeutics's investors include Bob Moore, Horizons Ventures, Bryan Roberts.
Kelonia Therapeutics has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in April 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 28, 2022 | $50M Series A | — | BOB Moore, Horizons Ventures, Bryan Roberts | Announced |